99 / 1498
•
Still a role for watch & wait in asymptomatic pts
•
Wait for indication of treatment
•
Combined R-chemo standard; R-CHOPmost often used
•
No clear superiority of R-CHOP over R-CVP
•
BR with longer PFS and lower toxicity
•
R-chemo plus R-maintenance current best option in follicular
particularly in relapsed disease
•
No relevant role for high-dose chemo and ASCT
•
Perspectives: Bortezomib, Lenalidomide, Obinutuzumab (GA101),
Ofatumumab, Temsirolimus, Ibrutinib, Idelalisib, ABT-199
Standard of care in pts with indolent lymphomas